Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Median Effective Volume and Concentration of Ropivacaine for Shoulder Analgesia via Anterior Suprascapular Nerve Block
ChiCTR2300070129Phase 4Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ropivacaine in shoulder pain (2 arms), sponsored by Nanjing First Hospital. Primary endpoints: 50% minimum effective volume (MEV50) of ropivacaine for aSSNB and 50% minimum effective concentration (MEC50) of ropivacaine for aSSNB. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
shoulder pain
Beyond the preview
Go deeper on ChiCTR2300070129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070129.